Loading stock data…
OKYO
$1.66+0.07 (+4.40%)
Market ClosedLast close May 1
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OKYO Pharma Limited in the Healthcare sector is trading at $1.66. The stock is currently near its 52-week low of $1.32, remaining 21.7% below its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why OKYO maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.66
Potential Upside
5%
Whystock Fair Value$1.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
135.08%
Volume
Today's trading volume
89,675
Recent News
OKYO Pharma to hold Scientific Advisory Board meeting at ASCRS 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company focused on treatments for neuropathic corneal pain (NCP) and inflammatory eye diseases, has announced plans to convene a Scientific Advisory Board (SAB) meeting during the 2026 American Society of Cataract and Refractive...
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy urcosimod in a mid-stage study for neuropathic corneal pain (NCP), a chronic eye condition with no approved treatments. The clinical-stage...
Dow Jones sheds more than 800 points on Trump's latest tariff threat
4:15pm: Tariff fallout Trump’s new global tariffs saw US stocks finish the day firmly in the red. The Dow Jones fell 1.7% or about 820 points to 48,804 points, the Nasdaq was down 1.1% at 22,627 points and the S&P 500 fell 1% to 6,837 points. 3:30pm: Proactive news headlines OKYO...
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026...
Nasdaq posts slim gain in calm trade as Wall Street inches up
Wall Street is reopening after the long weekend with investors still grappling with the recent pullback in technology shares